Caffeine (Coffein) Veterinary Grade API is the anhydrous 1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione entity supplied for the manufacture of tablets, injections, capsules, powders, granules, medicated premixes, and oral or parenteral solutions. The substance is indexed under CAS 58-08-2, has the molecular formula C8H10N4O2, and a relative molecular mass of 194.19 g/mol. The compendial material appears as a white or almost white crystalline powder or silky needles and is sparingly soluble in water and ethanol; aqueous solubility rises sharply near boiling point. The product is not a formulation, but a controlled active pharmaceutical ingredient whose certificate of analysis must be aligned with the downstream route of administration. For tablets, capsules, powders, granules, and premixes, the controlling parameters are particle size, bulk/tapped density, blend uniformity, loss on drying, and microbial quality. For injections and sterile solutions, the controlling parameters expand to bacterial endotoxins, particulate matter, and sterility-relevant bioburden. The product model is supplier-specific; no universal pharmacopoeial designation exists for crystalline, milled, micronised, direct-compression, or injectable low-endotoxin grades.

Compendial control of the material is anchored to the Ph.Eur. monograph Caffeine anhydrous 0267 and the corresponding USP caffeine monograph. Routine lot release includes assay on the dried basis, related substances by liquid chromatography, loss on drying, sulfated ash, residual solvents according to ICH Q3C and VICH GL18, elemental impurities according to ICH Q3D, and microbial examination when non-sterile or sterile processing is intended. Production-scale records from milling and sifting operations indicate that the main batch-to-batch variable is not chemical purity but particle-size distribution and crystal aspect ratio. Caffeine that crystallises as long needles can segregate in low-shear tumble blending; a milled or spheronised grade reduces the segregation tendency but increases surface energy and moisture uptake. “Caffeine (Coffein)” is therefore not a single physical model: different grades are defined by sieve cut, laser-diffraction D50, LOD, and powder-flow properties.

Unlike food-grade caffeine extracted from coffee, tea, or cola streams, the veterinary API is distinguished by a defined impurity profile and a full audit trail under Good Manufacturing Practice for active substances. Technical-grade caffeine may contain unidentified methylxanthine by-products, carryover solvent from methylation steps, or colour bodies that interfere with HPLC quantification. Food-grade material, although safe for human consumption, is not routinely tested for bacterial endotoxins or residual solvent class 1/2 levels, and its particle-size distribution is rarely controlled to pharmaceutical specifications. Veterinary grade does not necessarily imply natural or synthetic origin; both synthetic and extracted sources can qualify if the purification train and specification are the same.

What are the compendial limits that define the dry veterinary API?

Because the dry API is used in both non-sterile and sterile downstream operations, the release specification is divided into core compendial attributes and route-specific attributes. Core attributes are listed in Table 1.

Assay values are calculated on the dried basis; the 98.5–101.0% range is a chemical purity indicator, not a biological potency specification. The related-substances method separates caffeine from theobromine, theophylline, and other purine alkaloids; total related substances ≤ 0.5% is a compendial release limit. Residual solvents are confirmed by headspace GC-FID or GC-MS using reference standards for class 1 and class 2 solvents. Elemental impurities are controlled only if a risk assessment identifies a possible route of introduction from catalysts, process water, or container closure; a veterinary marketing authorisation may not require routine release testing for every element listed in ICH Q3D. For injectable grades, a bacterial endotoxin limit such as ≤ 0.5 EU/mg is not a default; it must be derived from the maximum daily dose and route, using the finished product monograph.

Crystal habit, particle design, and the shear response of caffeine API in dry processing

Unmilled caffeine anhydrous frequently presents as silky needles with a high aspect ratio. Under low shear in V-blenders or double-cone tumblers, needle-shaped crystals can segregate by size and orientation. On pharmaceutical tablet presses, such crystal habit may produce variable fill weight and punch filming, especially at turret speeds above 40 rpm depending on tooling. Milling through a pin mill or air-jet mill shifts the particle-size distribution to a D50 in the range 20–50 µm and D90 below 100 µm, but this does not automatically improve flow. The milled powder may exhibit a Hausner ratio above 1.35 and a Carr index above 25, indicating poor flow unless the formulation contains glidant and a coarse diluent.

For direct compression, the API is typically blended with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and 0.5–1.0 wt% magnesium stearate. Over-lubrication with magnesium stearate above 2.0 wt% can reduce tablet tensile strength because of hydrophobic film formation on binder surfaces. In wet granulation, low-viscosity povidone or hypromellose is dissolved in purified water, and caffeine is granulated in a high-shear granulator or fluid-bed granulator; inlet air temperatures between 50°C and 65°C are common but published data for this specific configuration is limited. The dried granulate is milled through a 1.0–1.5 mm screen before final blending. Tablets containing caffeine are often small and high-potency; content uniformity is controlled by Ph.Eur. 2.9.40 or USP <905>, with an acceptance value ≤ 15.0 for 10 dosage units.

For capsules, a sieve cut below 500 µm is usually specified to avoid segregation and to permit reproducible filling on dosator or tamping pin machines. Powder flow on a Schulze ring shear tester or a Freeman FT4 rheometer is part of product specification only when capsule or tablet fill lines require it. The API supplier’s particle design should be selected to match the downstream line; a grade that flows in a gravity-fed encapsulation machine may still segregate in a low-shear premix ribbon blender.

If a premix or granule formulation is specified, dry-matrix segregation becomes the dominant risk

Medicated premixes and granules require a different quality lens because the active is present at low carryover mass in a large diluent matrix. Caffeine API is first passed through a screening step, typically 0.5–1.0 mm mesh, and then geometrically diluted with carrier materials such as lactose monohydrate, maize starch, or mineral carriers. In ribbon-blender scale-up, the low active concentration can produce a coefficient of variation in blend uniformity greater than 5.0% if the API and carrier particle-size distributions overlap poorly. Blend uniformity testing follows Ph.Eur. 2.9.40 or equivalent USP <905> principles, with sampling thief consistency and assay precision being the main practical limitations.

Premix stability is governed by moisture migration and oxidative stress. The API is chemically stable at ambient temperature, but localised humidity during warehouse storage can induce caking. Bulk packaging should maintain a low moisture vapour transmission rate; opened containers stored at relative humidity above 60% should be re-equilibrated or used within a validated holding time. Granule production by fluid-bed spray granulation introduces a binder solution, usually povidone in water, and drying to a final LOD below 2.0% is generally required for non-sterile granules. The final blend must be protected from cross-contamination because caffeine is pharmacologically active at milligram-level doses; dedicated or validated cleaning between batches is required under EU GMP Part II and 21 CFR 211 manufacturing practice.

What are the injection-solution boundaries for the dry API?

Injectable grade caffeine API is manufactured with stricter bioburden and endotoxin controls. The aqueous solubility of caffeine anhydrous is limited at ambient temperature; concentrated injectable solutions may require the use of buffering or a co-solvent system, but the dry API itself is only sparingly soluble. In practice, caffeine citrate or caffeine/sodium benzoate combinations are often used for aqueous injection because they are more soluble than the anhydrous free base; however, the product described here is the anhydrous API intended for further salt formation or co-solvent formulation. For aqueous solutions, final pH is usually maintained between 4.0 and 7.0, and the solution is sterilised by terminal autoclaving at 121°C for 15 min after sterile filtration. Published data for this specific configuration is limited, so each formulation requires thermal stability testing, pH drift measurement, and subvisible particle assessment.

Bacterial endotoxins are controlled according to Ph.Eur. 2.6.14. The compendial API monograph may not include an endotoxin limit; a finished-product marketing authorisation must set a limit based on the maximum daily dose and route. For intravenous veterinary formulations, the endotoxin limit is typically calculated as 5 EU/kg/h for systemic administration, but this is product-specific. The dry API should be sampled in a clean area and handled with aseptic control only if terminal sterilisation is not available. Subvisible particulate matter in the final solution is controlled by Ph.Eur. 2.9.19 or USP <788> for filled containers, not solely by API specification.

Replacement of caffeine citrate with caffeine anhydrous in oral dosage forms changes the dissolution design space

When the free base is used instead of a more soluble salt, dissolution testing becomes the rate-limiting release test. Caffeine anhydrous is weakly basic and remains largely un-ionized across gastrointestinal pH values, so dissolution is controlled by particle surface area and wetting rather than by pH. The test is performed according to Ph.Eur. 2.9.3 or USP <711> in 900 mL of dissolution medium at 37°C, using paddle or basket apparatus. For immediate-release tablets, a specification of Q ≥ 80% dissolved in 30 min is commonly applied, but the exact limit is product-specific. If the tablet contains microcrystalline cellulose and croscarmellose sodium, fast disintegration may mask poor API dissolution; if the tablet is over-lubricated, the dissolution curve flattens because hydrophobic magnesium stearate retards wetting.

For capsules and granules, dissolution testing is often run with the same media and apparatus; the critical processing variable is the particle-size distribution of the caffeine, because the dissolution rate is proportional to the specific surface area. A milled grade with D50 near 20 µm may dissolve more rapidly than a crystalline grade with D50 near 100 µm; however, fine particles may aggregate, so a wetting agent such as polysorbate 80 is sometimes used at 0.01–0.1% in the dissolution medium if low solubility limits sink conditions.

Because caffeine is a central nervous system stimulant, the API should be handled as a pharmacologically active substance. Operator exposure limits are not harmonised; local occupational exposure bands may require containment and dust extraction in milling and sampling suites. In food-producing species, the regulatory status of caffeine is not uniform; use in a veterinary medicinal product is permitted only where a competent authority has granted a marketing authorisation or equivalent route. The dry substance should be stored in a tightly closed container, protected from light, and kept at controlled room temperature. Avoid direct contact with strong oxidising agents and extreme alkaline conditions, which can destabilise the purine ring and generate non-compendial degradation products.